When Canadian researchers randomly assigned 47 postmenopausal women to two groupsresistance training (three days/week for 12 months) plus creatine supplementation or resistance training plus placebo, those in the creatine group were more successful in staving off bone loss at the femoral neck (the tip-top of the thighbone, a hotspot for osteoporotic fractures)
The pivotal trials are STEP (semaglutide for weight management, The New England Journal of Medicine , 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)
Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms
Combining GLP-1 therapy with lifestyle optimization Neither orforglipron nor tirzepatide works optimally in isolation
Body Contouring For GLP-1 Patients: Evaluating Ultherapy PRIME According to a study in May 2024, approximately 12% of American adults have taken GLP-1 medications, with 6% of people polled actively taking them at the time of the survey
Nyligen har anskan om godknnande fr behandling av erytropoetisk protoporfyri, en genetisk sjukdom som karakteriseras av ljusintolerans, lmnats till European Medicines Agency [15]
